Brandon Folkes
Stock Analyst at HC Wainwright & Co.
(0)
# 4608
Out of 5,356 analysts
75
Total ratings
33.33%
Success rate
-15.58%
Average return
Main Sectors:
| Name | Action | PT | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
MIST Milestone Pharmaceut... | Assumes: Buy | 5 | 1.73 | 189.02% | 2 | Jun 5, 2025 | |
CRDL Cardiol Therapeutics | Initiates Coverage On: Buy | 9 | 1.38 | 552.17% | 1 | Jun 2, 2025 | |
PYPD PolyPid | Assumes: Buy | 11 | 3.16 | 248.1% | 2 | Jun 2, 2025 | |
TRVI Trevi Therapeutics | Initiates Coverage On: Buy | 21 | 6.77 | 210.19% | 2 | May 28, 2025 | |
RMTI Rockwell Medical | Initiates Coverage On: Buy | 5 | 0.97 | 415.46% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 12 | 3.53 | 239.94% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 9 | 3.9 | 130.77% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 9 | 3.27 | 175.23% | 2 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 8 | 0.66 | 1112.12% | 1 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 16 16 | 6.08 | 163.16% | 6 | Sep 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 13 | 13.2 | -1.52% | 1 | Aug 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 8 | 4.3 | 86.05% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 7 | 2 | 250% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 10 | 0.53 | 1786.79% | 2 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 455 | 6.36 | 7054.09% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 59 | 28.78 | 105% | 4 | Sep 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 8 | n/a | n/a | 4 | Sep 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 180 | 108.81 | 65.43% | 2 | Aug 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 15 | n/a | n/a | 2 | Jan 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 22 | 0.6 | 3566.67% | 3 | Dec 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 5 | n/a | n/a | 1 | Nov 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 6 | n/a | n/a | 1 | Jun 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 9 | 7.57 | 18.89% | 1 | Feb 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 28 32 | 31.05 | 3.06% | 3 | Jan 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 40 | n/a | n/a | 1 | Sep 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 22000 | 1.91 | 1151732.46% | 1 | Aug 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 30 22 | 29.47 | -25.35% | 5 | Aug 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 3125 | n/a | n/a | 1 | Aug 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 38 53 | n/a | n/a | 4 | Aug 20, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 78 40 | 59.83 | -33.14% | 3 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Overweight | 405 315 | n/a | n/a | 3 | Mar 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 58 46 | n/a | n/a | 6 | Mar 2, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 32 42 | n/a | n/a | 2 | Sep 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 42 50 | 16.16 | 209.41% | 1 | Jul 12, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 4 | n/a | n/a | 2 | Mar 13, 2018 |